Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from healthy individuals and sarcoidosis patients.
Golec. M M; Reichel. C C; Lemieszek. M M; Buczkowski. J J; Mackiewicz. B B; Skórska. C C; Dutkiewicz. J J; Góra. A A; Ziesche. R R; Milanowski. J J
Key Findings
- LL-37 concentrations in bronchoalveolar lavage fluid were significantly higher in sarcoidosis patients than in healthy controls.
- Elevated LL-37 levels were also observed in the epithelial lining fluid of sarcoidosis patients, mirroring the BALF findings.
- The study suggests a possible role for LL-37 in the pathogenesis of pulmonary sarcoidosis, but does not explore therapeutic implications.
Practical Outcomes
- For biohackers, this research mainly adds a piece of disease‑related biology and does not provide actionable steps, dosing advice, or protocols for LL-37 supplementation. Until intervention studies are done, there is no clear way to leverage this information for longevity, metabolic health, or performance enhancement.
Summary
The study measured the natural antimicrobial peptide LL-37 in lung fluids of people with sarcoidosis, a lung disease, and found higher levels compared to healthy volunteers. This suggests LL-37 may be involved in the disease process, but the research does not test any treatments or give guidance on using LL-37 for health improvement.
Abstract
Sarcoidosis is a granulomatous disease of unknown etiology most often characterized by pulmonary manifestations. Changes in an innate immune system, involving antimicrobial peptides, have been noted during the course of pulmonary sarcoidosis. This study focuses on the level of LL-37 peptide, the only human cathelicidin, additionally characterized by a wide range of pleiotropic activities, in pulmonary sarcoidosis. A cross-sectional study was conducted in groups of 32 patients with sarcoidosis and 12 healthy individuals. Bronchoalveolar lavage fluid (BALF) sampling, followed by LL-37 measurements by mass spectrometry combined with previous immunoaffinity purification, was performed. Based on urea levels, concentrations of LL-37 in epithelial lining fluid (ELF) were calculated. The levels of LL-37 peptide in BALF samples derived from patients with pulmonary sarcoidosis (median: 17.45 pg/ml, 25th-75th percentile: 8.05-28.33 pg/ml) were significantly higher compared to the healthy group (median: 6.38 pg/ml, 25th-75th percentile: 4.90-11.55 pg/ml) (U Mann-Whitney test, p=0.04). Assessment of LL-37 in ELF confirmed the differences across the groups that were observed in BALF. The level of LL-37 in patients with sarcoidosis (median: 2.25 ng/ml, 25th-75th percentile: 1.03-5.06 ng/ml) was again higher compared to healthy individuals (median: 0.62 ng/ml, 25th-75th percentile: 0.43-2.17 ng/ml) (p=0.06, Mann-Whitney U test). The results of this study demonstrate that the level of LL-37 peptide is elevated in pulmonary compartment affected by sarcoidosis. This might have a meaning in the pathomechanism of the disease, especially taking into consideration versatile activity of human cathelicidin revealed in numerous experimental studies during the last years.
Study Information
pubmed
2014